Aging, Risk of falling, Cognition, Quality of life, Balance, Physical exercise, Epigenetics
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: age over 60 and have ability to walk without bracing
Exclusion criteria
Exclusion criteria: Make use of medicines containing HDAC inhibitor such as Acid Valproic, have other associated neurological diseases, problems orthopedic and / or musculoskeletal disorders that affect gait, cognitive impairment Mini Mental State Examination (MMSE), inability to communicate with investigators or have no medical clearance to perform physical activity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1 (clinical-functional) The intervention was expected to improve clinical-functional outcomes in elderly people. The research techniques and instruments used were as follows: Montreal Cognitive Assessment (MoCA) questionnaire to assess cognition; to assess quality of life, the questionnaire developed by the World Health Organization Whoqol-Bref was used; to determine sarcopenia, dynamometry (upper limb strength) and 10-meter walk test (gait speed) and calf circumference (muscle trophism) were performed; the risk of falls was assessed using the Berg Balance Scale; the Time Up and Go Test was used to assess balance; functionality was determined by the Katz index and functional capacity by the six-minute walk test; anthropometric data included: waist circumference, weight, height and body mass index (BMI).;Outcome found 1 (clinical-functional) There was a significant improvement in all clinical and functional outcomes evaluated, except in handgrip strength (dynamometry). Quality of life and cognition also showed significant improvement after the intervention protocol. ;Expected outcome 2 (epigenetic markers) The intervention was expected to be able to modulate epigenetic markers and increase levels peripheral BDNF in the elderly. Blood collection was performed to assess epigenetic markers, where epigenetic markers were measured in peripheral blood, measured using commercial kits according to the manufacturer's instructions.;Outcome found 2 (epigenetic markers) The only epigenetic marker measured so far was histone H4 acetylation levels, where no significant changes were found between the pre and post intervention moments. However, as cognition improved, we expect global histone H3 acetylation levels and BDNF levels to improve positively. | — |
Secondary
| Measure | Time frame |
|---|---|
| Predicted secondary outcomes There was a possibility that the sample number (proposed n was 15 volunteers) initially proposed by means of statistics not being reached, since the study depended on the availability of other people and not the researcher. In addition, significant differences in the effect of the intervention on the variables evaluated could not be observed, rejecting the hypothesis proposed in the study.;Secondary outcomes found The sample number was not reached, we obtained a number of 10 volunteers. All clinical functional outcomes improved significantly after the intervention protocol, including cognition and quality of life. Dynamometry (handgrip strength), however, did not show significant changes. The data of epigenetic markers dosed to date (histone H4 acetylation globules) also did not show significant changes, but it is expected that the other dosages demonstrate changes since the literature describes the specificity of exercise in the modulation of histones, mainly. | — |
Countries
Brazil
Contacts
Centro Universitário Metodista IPA